20/20 Genesystems Inc.
12/18/2025 | Press release | Distributed by Public on 12/18/2025 16:27
Amendment to Annual Report under Regulation A (Form 1-K/A)
| Form 1-K Issuer Information |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-K |
OMB APPROVAL |
|
|
OMB Number: 3235-0720 Estimated average burden hours per response: 600.0 |
1-K: Filer Information
| Issuer CIK |
0001139685
|
| Issuer CCC |
XXXXXXXX
|
| Is filer a shell company? | Yes No |
| Is the electronic copy of an official filing submitted in paper format? | |
| File Number |
24R-00172
|
| Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? | Yes No |
| Successor File Number |
|
| Is this a LIVE or TEST Filing? | LIVE TEST |
| Would you like a Return Copy? | |
| Period |
12-31-2024
|
| Name |
|
| Phone |
|
| E-Mail Address |
|
| Notify via Filing Website only? |
1-K: Tab 1 Notification
| This Form 1-K is to provide an | Annual Report Special Financial Report for the fiscal year |
| Fiscal Year End |
12-31-2024
|
| Exact name of issuer as specified in the issuer's charter |
20/20 Biolabs, Inc.
|
| CIK |
0001139685
|
| Jurisdiction of Incorporation / Organization |
DELAWARE
|
| I.R.S. Employer Identification Number |
57-2272107
|
Address of Principal Executive Offices
| Address 1 |
15810 Gaither Road
|
| Address 2 |
Suite 235
|
| City |
Gaithersburg
|
| State/Country |
MARYLAND
|
| Mailing Zip/ Postal Code |
20877
|
| Phone |
240-453-6339
|
| Title of each class of securities issued pursuant to Regulation A |
Series B Preferred Stock and Series C Preferred Stock
|
20/20 Genesystems Inc. published this content on December 18, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 18, 2025 at 22:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]